Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 5/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2325489 | 1.00 | CHRM5 (0.44) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL29747907 | 1.00 | CHRM5 (0.44) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL29747213 | 1.00 | CHRM5 (0.44) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL2328010 | 1.00 | CHRM5 (0.44) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| Hydrochloric Acid SCHEMBL2324252 | 0.98 | CHRM5 (0.43) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| Hydrochloric Acid SCHEMBL2324247 | 0.98 | CHRM5 (0.43) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL25235310 | 0.94 | CYP2D6 (0.45) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL27761854 | 0.79 | MEN1 (0.41) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL23323069 | 0.78 | CHRM5 (0.46) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL22165430 | 0.78 | CHRM5 (0.46) | CHRM5CHRM3CHRM2CHRM1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132123-A1 | ABAD INHIBITOR COMPOUNDS | UNIV COURT OF THE UNIV OF ST ANDREWS (GB) | 2026-05-14 | — | — | US | disclosed |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12583853-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12552784-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| US-12077536-B2 | BCL-2 inhibitors | BEIGENE, LTD. (KY) | 2024-09-03 | — | — | US | disclosed |
| EP-4392412-A1 | ABAD INHIBITOR COMPOUNDS | University Court of The University of St Andrews (GB) | 2024-07-03 | — | — | EP | disclosed |
| US-20240166646-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | NEWAVE PHARMACEUTICAL INC. | 2024-05-23 | — | — | US | disclosed |
| WO-2012034095-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
| CN-102203077-A | (pyrrolidin-2-yl) phenyl derivatives for the treatment of pain | ORGANON NV | 2011-09-28 | — | — | CN | disclosed |
| EP-2356105-A1 | ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN | N.V. Organon (NL) | 2011-08-17 | — | — | EP | disclosed |
| EP-2260020-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | Novartis AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| WO-2010052198-A1 | ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN | N.V. ORGANON (NL) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010052198-A1 | ( PYRROLIDIN-2 -YL) PHENYL DERIVATIVES FOR USE IN THE TREATMENT OF PAIN | N.V. ORGANON (NL) | 2010-05-14 | — | — | WO | disclosed |
| US-20100113493-A1 | (PYRROLIDIN-2-YL)PHENYL DERIVATIVES | N.V. ORGANON | 2010-05-06 | — | — | US | disclosed |
| US-20100113493-A1 | (PYRROLIDIN-2-YL)PHENYL DERIVATIVES | N.V. ORGANON | 2010-05-06 | — | — | US | disclosed |
| US-20100113493-A1 | (PYRROLIDIN-2-YL)PHENYL DERIVATIVES | N.V. ORGANON | 2010-05-06 | — | — | US | disclosed |
| WO-2009118305-A1 | HYDROXAMATE-BASED INHIBITORS OF DEACETYLASES B | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166646-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | BCL2, BCL3, BCL2L1 | CHRM5 4783/4885CHRM3 4845/4885CHRM2 4666/4885 |
| US-20100113493-A1 | (PYRROLIDIN-2-YL)PHENYL DERIVATIVES | CNR1, CNR2, TRPV1 | CHRM5 2063/4885CHRM3 1989/4885CHRM2 1173/4885 |
| US-12077536-B2 | BCL-2 inhibitors | BCL2, BCL2L1, BCL2L2 | CHRM5 4880/4885CHRM3 4877/4885CHRM2 4863/4885 |
| US-20260132123-A1 | ABAD INHIBITOR COMPOUNDS | ADH1C, ADH1A, CBR1 | CHRM5 1105/4885CHRM3 1311/4885CHRM2 1326/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | CHRM5 4869/4885CHRM3 4860/4885CHRM2 4628/4885 |
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | CHRM5 4880/4885CHRM3 4877/4885CHRM2 4863/4885 |
| US-12583853-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | BCL3, BCL9, BCL6 | CHRM5 2431/4885CHRM3 3074/4885CHRM2 2597/4885 |
| US-12552784-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | BCL3, BCL2A1, BCL6 | CHRM5 1896/4885CHRM3 3085/4885CHRM2 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.